Having trouble accessing articles? Reset your cache.

Adverum gains on Phase I data showing efficacy for wet AMD gene therapy

Updated interim data for Adverum’s intravitreal wet age-related macular degeneration gene therapy bolstered the company’s case that the product could compete with less convenient subretinal gene therapies for the indication.

Adverum rose $1.81 (18%) to $12.05 on Monday.

The data, which included results from the second cohort in the Phase I OPTIC trial of

Read the full 538 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE